Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical research trials and YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "Y" Clinical Trials Conditions > YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy



YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

For Condition: Hormone-Refractory Prostate Cancer,Prostatic Neoplasms
Status: Terminated
Sponsor(s): Yamanouchi Pharma America ,
Synopsis: The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: 
Total Enrollment: 

Location and Contact Information:

Southern Medical Day Care Centre
Wollongong,  , 
Australia
 

Department of Urological Research, Derriford Hospital
Devon,  , 
United Kingdom
 

University of Chicago, Section of Hematology/Oncology
Chicago,  Illinois, 
United States
 

Michiana Hematology/Oncology
South Bend,  Indiana, 
United States
 

Henry Ford Hospital
Detroit,  Michigan, 
United States
 

Hospital Clinic i Provincial, Servicio de Oncologia
Barcelona,  , 
Spain
 

University of Illinois, Department of Urology
Chicago,  Illinois, 
United States
 

Dept Urology University of Essen
ESSEN,  , 
Germany
 

Shands Hospital
Gainesville,  Florida, 
United States
 

Klinika Nowotworow Ukladu
Warszawa,  , 
Poland
 

Department of Medical Oncology, Concord Hospital Medical Centre
Concord,  , 
Australia
 

Imperial College School of Medicine, Dept Cancer Medicine
London,  , 
United Kingdom
 

Urologische Klinik der MHH
Hannover,  , 
Germany
 

Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie
Utrecht,  , 
Netherlands
 

Hospital Universitario PrĂ­ncipe de Asturias, Servicio de UrologĂ­a
Madrid,  , 
Spain
 

Krankenhause am Urban, Urologie Dieffenfachstr
Berlin,  , 
Germany
 

Cancer Care Centre, St. George Hospital
Sydney,  , 
Australia
 

Klinikum Mannheim Urology
Mannheim,  , 
Germany
 

Hospital General Vall d'Hebron, Servicio de OncologĂ­a
Barcelona,  , 
Spain
 

Oddzial Chemioterapii
Krakow,  , 
Poland
 

Szpital CSK WAMl, Klinika Okologii
Warsaw,  , 
Poland
 

Sylvester Comprehensive Cancer Center
Miami,  Florida, 
United States
 

Centre Paul Papin
Angers,  , 
France
 

Cliniques Universitaires St-Luc, Service d'Urologie
BRUXELLES,  , 
Belgium
 

Washington University School of Medicine
St. Louis,  Missouri, 
United States
 

San Bernardino Urological Associates
San Bernardino,  California, 
United States
 

Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow
Tarnow,  , 
Poland
 

Service d' Urologie CHU, Hopital Bichat
Paris,  , 
France
 

Department of Medical Oncology, The Canberra Hospital
Canberra,  , 
Australia
 

Department of Urology, St Bartholomew's Hospital
London,  , 
United Kingdom
 

Department of Medical Oncology, Newcastle Mater Hospital
Waratah,  , 
Australia
 

Western Clinical Research, Inc.
Torrance,  California, 
United States
 

Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie
Krakow,  , 
Poland
 

St Richard's Hospital
West Sussex,  , 
United Kingdom
 

Instituto Valenciano de Oncologia, Servicio de Oncologia
Valencia,  , 
Spain
 

Royal Surrey County Hospital
Surrey,  , 
United Kingdom
 

The Urologic Institute of New Orleans
Gretna,  Louisiana, 
United States
 

Georgia Urology,PA Research Institute
Atlanta,  Georgia, 
United States
 

Pavillon V, Service d'Urologie et de transplatation, HĂ´pital Edouard Herriot
Lyon,  , 
France
 

Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii
Opole,  , 
Poland
 

Klinika Chemioterapii AM
Lodz,  , 
Poland
 

Queen Elizabeth Hospital, Clinical Hematology & Oncology
Woodville,  , 
Australia
 

Mater Misericordiae Hospital
Dublin,  , 
Ireland
 

Memphis Cancer Center
Memphis,  Tennessee, 
United States
 

Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie
Charleroi,  , 
Belgium
 

Service d'Urologie, HĂ´pital Henri Mondor
Creteil,  , 
France
 

Hospital Universitario de Getafe, Servicio de Urologia, Crta
Getafe (Madrid),  , 
Spain
 

Department of Urology, East Surrey Hospital
Surrey,  , 
United Kingdom
 

Clinical Research Centre, St George's Hospital, Urology Division
London,  , 
United Kingdom
 

Department of Clinical Oncology, Royal North Shore Hospital
St. Leonards,  , 
Australia
 

Alaska Clinical Research Center, LLC
Anchorage,  Alaska, 
United States
 

Division of Oncology Ward, Royal Brisbane Hospital
HERSTON,  , 
Australia
 

Virginia Mason Medical Center
Seattle,  Washington, 
United States
 


Additional Information:
Study ID Numbers:
  598-CL-008; 
Study Start Date: 
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048659

Other Hormone-Refractory Prostate Cancer Studies:
1. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

2. Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel

Related Studies:

Other Hormone-Refractory Prostate Cancer Clinical Trials
Other Clinical Trials
Other Madrid Clinical Trials

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Modify your Search

  Other Hormone-Refractory Prostate Cancer Clinical Trials
  Other Clinical Trials
  Other Madrid Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103